REG - Amgen Inc. Horizon Therapeutics - Form 8 (OPD) - Horizon Therapeutics Plc

AmgenAnnouncement

13/12/2022 12:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221213:nRSM5587Ja&default-theme=true

RNS Number : 5587J  Amgen Inc.  13 December 2022

 

FORM 8.1(a) & (b)

(OPD)

 

IRISH TAKEOVER PANEL

 

OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER
PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE

 

1.             KEY INFORMATION

 

 (a)  Full name of discloser:                                                    AMGEN INC.
 (b) Owner or controller of interests and short positions disclosed, if          N/A
 different from 1(a):

 The naming of nominee or vehicle companies is insufficient. For a trust, the
 trustee(s), settlor and beneficiaries must be named.
 (c)  Name of offeror/offeree in relation to whose relevant securities this      HORIZON THERAPEUTICS PLC
 form relates:

 Use a separate form for each offeror/offeree
 (d)  Is the discloser the offeror or the offeree?                               OFFEROR
 (e)  Date position held:                                                        12 DECEMBER 2022

 The latest practicable date prior to the disclosure
 (f)   In addition to the company in 1(c) above, is the discloser also making    N/A
 disclosures in respect of any other party to the offer?

 If it is a cash offer or possible cash offer, state "N/A"

 

2.             INTERESTS AND SHORT POSITIONS

 

If there are interests and positions to disclose in more than one class of
relevant securities of the offeror or offeree named in 1(c), copy table 2 for
each additional class of relevant security.

 

 

Interests and short positions in the relevant securities of the offeror or
offeree to which the disclosure relates (Note 1)

 

 Class of relevant security: Ordinary shares of $0.0001 each in the capital of
 Horizon Therapeutics plc
                                                                        Interests      Short positions
                                                                        Number  %      Number    %
 (1)  Relevant securities owned and/or controlled:                      Nil     -      Nil       -
 (2)  Cash-settled derivatives:                                         Nil     -      Nil       -
 (3)  Stock-settled derivatives (including options) and agreements to   Nil     -      Nil       -
 purchase/ sell:
 Total:                                                                 Nil     -      Nil       -

 

All interests and all short positions should be disclosed.

 

Details of options including rights to subscribe for new securities and any
open stock-settled derivative positions (including traded options), or
agreements to purchase or sell relevant securities, should be given on a
Supplemental Form 8.

 

3.             INTERESTS AND SHORT POSITIONS OF PERSONS ACTING IN
CONCERT WITH THE PARTY MAKING THE DISCLOSURE

 

 Details of any interests and short positions (including directors' and other
 employee options) of any person acting in concert with the party making the
 disclosure:
 Concert Party Details                                                           Interest Details                    Percentage of Issued Ordinary Shares
 Robert A. Eckert Living Trust (a related trust of Robert A. Eckert, a director  86 ordinary shares of $0.0001 each  0.000038%
 of Amgen Inc.)

 

Details of any open stock-settled derivative positions (including traded
options), or agreements to purchase or sell relevant securities, should be
given on a Supplemental Form 8.

 

 

 

 

4.             OTHER INFORMATION

 

(a)           Indemnity and other dealing arrangements

 

 Details of any indemnity or option arrangement, or any agreement or
 understanding, formal or informal, relating to relevant securities which may
 be an inducement to deal or refrain from dealing entered into by the party to
 the offer making the disclosure or any person acting in concert with it:

 Irrevocable commitments and letters of intent should not be included. If there
 are no such agreements, arrangements or understandings, state "none"
 None

 

(b)           Agreements, arrangements or understandings relating to
options or derivatives

 

 Full details of any agreement, arrangement or understanding between the person
 disclosing and any other person relating to the voting rights of any relevant
 securities under any option referred to on this form or relating to the voting
 rights or future acquisition or disposal of any relevant securities to which
 any derivative referred to on this form is referenced. If none, this should be
 stated.
 None

 

(c)           Attachments

 

 Is a Supplemental Form 8 attached?  NO

 

 Date of disclosure:  13 December 2022
 Contact name:        Arvind Sood
 Telephone number:    +1 805 447 1060

 

Public disclosures under Rule 8.1 of the Rules must be made to a Regulatory
Information Service.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ISEEAFADFALAFFA